SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) may offer an additional therapeutic option, as they have shown effectiveness in reducing HbA1c levels in patients with PL, with a safety profile similar to that of patients with common T2DM [71].